Novartis heads to the finish line with CDK 4/6 blockbuster contender ribociclib
In the final stretch in its journey to regulators, Novartis posted a positive snapshot of pivotal Phase III data on its CDK 4/6 contender ribociclib (LEE011), setting up a likely showdown with Pfizer in treating breast cancer.
The headline figure from ESMO is that ribociclib combined with letrozole reduced the risk of death or progression by 44% among first-line patients compared to letrozole alone, offering further encouragement to the pharma giant that it’s right on track to gaining an approval for this drug next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.